Irene Litvan,, Faan, Fana

List of Publications by Year
in descending order

393 papers	57,352 citations	2311 98 h-index	1185 228 g-index
409 all docs	409 docs citations	409 times ranked	32940 citing authors

#	Article	IF	Citations
1	Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology, 2005, 65, 1863-1872.	1.5	4,604
2	MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders, 2015, 30, 1591-1601.	2.2	4,389
3	The FAB. Neurology, 2000, 55, 1621-1626.	1.5	3,317
4	Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology, 1996, 47, 1-9.	1.5	2,510
5	Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders, 2007, 22, 1689-1707.	2.2	2,497
6	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Movement Disorders, 2012, 27, 349-356.	2.2	1,908
7	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nature Genetics, 2014, 46, 989-993.	9.4	1,685
8	Criteria for the diagnosis of corticobasal degeneration. Neurology, 2013, 80, 496-503.	1.5	1,445
9	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	2.2	1,402
10	MDS research criteria for prodromal Parkinson's disease. Movement Disorders, 2015, 30, 1600-1611.	2.2	1,033
11	Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. Movement Disorders, 2007, 22, 2314-2324.	2.2	885
12	Consensus statement on the diagnosis of multiple system atrophy. Clinical Autonomic Research, 1998, 8, 359-362.	1.4	823
13	Preliminary NINDS neuropathologic criteria for Steeleâ€Richardsonâ€Olszewski syndrome (progressive) Tj ETQq1 1 0.784314 rgBT /O	1.5	808
14	Association of an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy. Human Molecular Genetics, 1999, 8, 711-715.	1.4	749
15	Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurology, The, 2009, 8, 1150-1157.	4.9	734
16	The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathologica, 2016, 131, 75-86.	3.9	708
17	Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurology, The, 2009, 8, 1128-1139.	4.9	700
18	MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PDâ€MCI. Movement Disorders, 2011, 26, 1814-1824.	2.2	649

#	Article	IF	Citations
19	Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration. Journal of Neuropathology and Experimental Neurology, 2002, 61, 935-946.	0.9	592
20	Apathy Is Not Depression. Journal of Neuropsychiatry and Clinical Neurosciences, 1998, 10, 314-319.	0.9	554
21	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nature Genetics, 2011, 43, 699-705.	9.4	502
22	Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Annals of Neurology, 2003, 54, S15-S19.	2.8	496
23	Technology in Parkinson's disease: Challenges and opportunities. Movement Disorders, 2016, 31, 1272-1282.	2.2	464
24	Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology, 1996, 46, 922-930.	1.5	441
25	Accuracy of the Clinical Diagnosis of Corticobasal Degeneration. Neurology, 1997, 48, 119-125.	1.5	436
26	Validity and Reliability of the Preliminary NINDS Neuropathologic Criteria for Progressive Supranuclear Palsy and Related Disorders. Journal of Neuropathology and Experimental Neurology, 1996, 55, 97-105.	0.9	417
27	Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Human Genetics, 2009, 124, 593-605.	1.8	410
28	Cognitive planning deficit in patients with cerebellar atrophy. Neurology, 1992, 42, 1493-1493.	1.5	401
29	Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology, 2001, 56, 1702-1706.	1.5	392
30	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Movement Disorders, 2014, 29, 454-462.	2.2	379
31	Progression of Dysarthria and Dysphagia in Postmortem-Confirmed Parkinsonian Disorders. Archives of Neurology, 2001, 58, 259.	4.9	375
32	Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.. Journal of Neurology, Neurosurgery and Psychiatry, 1996, 60, 615-620.	0.9	357
33	Adenosine A_{2A} receptor antagonist istradefylline (KWâ€6002) reduces â€œoffâ€•time in Parkinson's disease: A doubleâ€blind, randomized, multicenter clinical trial (6002â€USâ€005). Annals of Neurology, 2008, 63, 295-302.	2.8	333
34	Accuracy of the Clinical Diagnoses of Lewy Body Disease, Parkinson Disease, and Dementia With Lewy Bodies. Archives of Neurology, 1998, 55, 969.	4.9	325
35	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. JAMA Neurology, 2014, 71, 543.	4.5	312
36	Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurology, The, 2017, 16, 552-563.	4.9	303

#	Article	IF	Citations
37	Natural history and survival of 14Âpatients with corticobasal degeneration confirmed at postmortem examination. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 184-189.	0.9	288
38	Metaâ€analysis of Parkinson's Disease: Identification of a novel locus, RIT2. Annals of Neurology, 2012, 71, 370-384.	2.8	264
39	Lrrk2 and Lewy body disease. Annals of Neurology, 2006, 59, 388-393.	2.8	259
40	A phase 2 trial of the GSKâ€3 inhibitor tideglusib in progressive supranuclear palsy. Movement Disorders, 2014, 29, 470-478.	2.2	251
41	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurology, The, 2014, 13, 676-685.	4.9	245
42	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Movement Disorders, 2015, 30, 919-927.	2.2	244
43	Î±-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinsonâ€™s disease. Nature Communications, 2020, 11, 1875.	5.8	239
44	Neuropsychiatric aspects of progressive supranuclear palsy. Neurology, 1996, 47, 1184-1189.	1.5	237
45	Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology, 1999, 53, 1292-1292.	1.5	224
46	Phosphorylated Î±-Synuclein in Parkinsonâ€™s Disease. Science Translational Medicine, 2012, 4, 121ra20.	5.8	223
47	What Is the Accuracy of the Clinical Diagnosis of Multiple System Atrophy?. Archives of Neurology, 1997, 54, 937.	4.9	222
48	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Movement Disorders, 2022, 37, 1131-1148.	2.2	222
49	Slowed Information Processing in Multiple Sclerosis. Archives of Neurology, 1988, 45, 281-285.	4.9	213
50	Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1215-1220.	0.9	199
51	Wearable Electrochemical Microneedle Sensor for Continuous Monitoring of Levodopa: Toward Parkinson Management. ACS Sensors, 2019, 4, 2196-2204.	4.0	196
52	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology, 2019, 92, 329-337.	1.5	194
53	Visualizing Cortical Activation during Mental Calculation with Functional MRI. NeuroImage, 1996, 3, 97-103.	2.1	192
54	Bilateral subthalamotomy in Parkinson's disease: initial and long-term response. Brain, 2005, 128, 570-583.	3.7	184

#	Article	IF	Citations
55	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. Movement Disorders, 2017, 32, 955-971.	2.2	179
56	Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 620-623.	0.9	171
57	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders, 2018, 33, 1601-1608.	2.2	171
58	Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. European Journal of Neurology, 2009, 16, 297-309.	1.7	170
59	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	5.8	170
60	Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology, 2001, 57, 467-473.	1.5	160
61	High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Human Molecular Genetics, 2005, 14, 3281-3292.	1.4	156
62	Multiple Memory Deficits in Patients With Multiple Sclerosis. Archives of Neurology, 1988, 45, 607.	4.9	155
63	A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Movement Disorders, 2010, 25, 2501-2507.	2.2	155
64	Environmental Exposures and Parkinsonâ€™s Disease. International Journal of Environmental Research and Public Health, 2016, 13, 881.	1.2	151
65	Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2001, 13, 42-49.	0.9	149
66	Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.7	148
67	The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2013, 1, 31.	2.4	148
68	¹⁸Fâ€flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. Annals of Neurology, 2017, 82, 622-634.	2.8	148
69	Neuropsychiatric features of corticobasal degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 717-721.	0.9	147
70	Influence of Heterozygosity for Parkin Mutation on Onset Age in Familial Parkinson Disease. Archives of Neurology, 2006, 63, 826.	4.9	147
71	Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. Neurology, 2000, 54, 1029-1032.	1.5	146
72	Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. NeuroImage, 2004, 21, 714-724.	2.1	145

#	Article	IF	Citations
73	Progression of falls in postmortem-confirmed Parkinsonian disorders. Movement Disorders, 1999, 14, 947-950.	2.2	144
74	Frontal Lobe Function in Progressive Supranuclear Palsy. Archives of Neurology, 1990, 47, 553-558.	4.9	140
75	Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology, 2009, 73, 1469-1477.	1.5	136
76	Importance of deficits in executive functions. Lancet, The, 1999, 354, 1921-1923.	6.3	135
77	Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain, 1997, 120, 1541-1552.	3.7	132
78	Progressive supranuclear gaze palsy is in linkage disequilibrium with theÏ„ and not the Î±-synuclein gene. Neurology, 1998, 50, 270-273.	1.5	128
79	Neuropsychiatric Assessment of Patients With Hyperkinetic and Hypokinetic Movement Disorders. Archives of Neurology, 1998, 55, 1313.	4.9	128
80	Update on epidemiological aspects of progressive supranuclear palsy. Movement Disorders, 2003, 18, 43-50.	2.2	121
81	"Applause sign" helps to discriminate PSP from FTD and PD. Neurology, 2005, 64, 2132-2133.	1.5	121
82	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	2.2	121
83	Measuring mild cognitive impairment in patients with Parkinson's disease. Movement Disorders, 2013, 28, 626-633.	2.2	120
84	Progressive supranuclear palsy. Neurology, 1998, 50, 1637-1647.	1.5	119
85	Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain, 2011, 134, 3264-3275.	3.7	119
86	Mild cognitive impairment as a risk factor for Parkinson's disease dementia. Movement Disorders, 2017, 32, 1056-1065.	2.2	117
87	A Reappraisal of Reliability and Validity Studies in Stroke. Stroke, 1996, 27, 2331-2336.	1.0	117
88	Evaluation of surgery for Parkinsonâ€™s disease. Neurology, 1999, 53, 1910-1910.	1.5	115
89	Movement disorder society criteria for clinically established early Parkinson's disease. Movement Disorders, 2018, 33, 1643-1646.	2.2	114
90	Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology, 2003, 60, 917-922.	1.5	113

#	Article	IF	Citations
91	Behavioral abnormalities in progressive supranuclear palsy. Psychiatry Research, 2013, 210, 1205-1210.	1.7	113
92	Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Movement Disorders, 2005, 20, 982-988.	2.2	111
93	The Second NINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy. Journal of Neuropathology and Experimental Neurology, 2021, 80, 210-219.	0.9	111
94	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. PLoS ONE, 2017, 12, e0175674.	1.1	110
95	Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurology, The, 2019, 18, 549-558.	4.9	108
96	Progression of Hoehn and Yahr stages in parkinsonian disorders: A clinicopathologic study. Neurology, 2000, 55, 888-891.	1.5	107
97	Fall Prediction and Prevention Systems: Recent Trends, Challenges, and Future Research Directions. Sensors, 2017, 17, 2509.	2.1	107
98	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Movement Disorders, 2010, 25, 1077-1081.	2.2	106
99	Pharmacological Therapy in Progressive Supranuclear Palsy. Archives of Neurology, 1998, 55, 1099.	4.9	105
100	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. Journal of Neuropathology and Experimental Neurology, 2007, 66, 251-257.	0.9	104
101	Genomewide association study for onset age in Parkinson disease. BMC Medical Genetics, 2009, 10, 98.	2.1	104
102	Haplotypes and gene expression implicate the MAPT region for Parkinson disease. Neurology, 2008, 71, 28-34.	1.5	103
103	The Gly2019Ser mutation in LRRK2is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Medicine, 2008, 6, 32.	2.3	102
104	Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 25-29.	0.9	100
105	Characterizing swallowing abnormalities in progressive supranuclear palsy. Neurology, 1997, 48, 1654-1662.	1.5	98
106	NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiology of Aging, 2015, 36, 1605.e7-1605.e12.	1.5	96
107	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	2.2	93
108	The RAB39B p.G192R mutation causes X-linked dominant Parkinsonâ€™s disease. Molecular Neurodegeneration, 2015, 10, 50.	4.4	91

#	Article	IF	Citations
109	4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathologica, 2020, 139, 63-77.	3.9	89
110	Implicit Learning in Patients with Alzheimer's Disease. Pharmacopsychiatry, 1990, 23, 94-101.	1.7	88
111	Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy. Neurology, 2001, 56, 957-963.	1.5	85
112	Î±â€šynuclein genetic variability: A biomarker for dementia in Parkinson disease. Annals of Neurology, 2016, 79, 991-999.	2.8	85
113	Reliability of the NINDS Myotatic Reflex Scale. Neurology, 1996, 47, 969-972.	1.5	83
114	Mitochondrial Dysfunction in Cybrid Lines Expressing Mitochondrial Genes from Patients with Progressive Supranuclear Palsy. Journal of Neurochemistry, 2002, 75, 1681-1684.	2.1	83
115	The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurology, The, 2016, 15, 546-548.	4.9	82
116	Utility of the global CDR^{Â®} plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium. Alzheimer's and Dementia, 2020, 16, 106-117.	0.4	81
117	What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. Neurology, 1997, 49, 62-69.	1.5	80
118	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression. JAMA - Journal of the American Medical Association, 2021, 326, 926.	3.8	80
119	Executive Dysfunction Is the Primary Cognitive Impairment in Progressive Supranuclear Palsy. Archives of Clinical Neuropsychology, 2013, 28, 104-113.	0.3	79
120	Progressive supranuclear palsy: a clinicopathological study of 21 cases. Acta Neuropathologica, 1996, 91, 427-431.	3.9	78
121	Assessment of cognition in early dementia. Alzheimer's and Dementia, 2011, 7, e60-e76.	0.4	75
122	Instrumental activities of daily living are impaired in Parkinsonâ€™s disease patients with mild cognitive impairment.. Neuropsychology, 2014, 28, 229-237.	1.0	75
123	Penguins and hummingbirds: Midbrain atrophy in progressive supranuclear palsy. Neurology, 2006, 66, 949-950.	1.5	74
124	Milestones in atypical and secondary Parkinsonisms. Movement Disorders, 2011, 26, 1083-1095.	2.2	74
125	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 182-192.	4.9	74
126	Language disturbances in corticobasal degeneration. Neurology, 2000, 54, 990-992.	1.5	72

#	Article	IF	Citations
127	Traumatic brain injury as a risk factor for Alzheimer disease. Comparison of two retrospective autopsy cohorts with evaluation of ApoE genotype. BMC Neurology, 2001, 1, 3.	0.8	69
128	Identification of a Novel Risk Locus for Progressive Supranuclear Palsy by a Pooled Genomewide Scan of 500,288 Single-Nucleotide Polymorphisms. American Journal of Human Genetics, 2007, 80, 769-778.	2.6	68
129	BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study. Neurology, 2005, 65, 1823-1825.	1.5	67
130	Copy Number Variation in Familial Parkinson Disease. PLoS ONE, 2011, 6, e20988.	1.1	67
131	Effects of closed traumatic brain injury and genetic factors on the development of Alzheimer's disease. European Journal of Neurology, 2001, 8, 707-710.	1.7	66
132	Selective deficits in cognition and memory in high-functioning parkinsonian patients.. Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 603-606.	0.9	65
133	Parkinsonian Syndromes. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 1189-1212.	0.4	65
134	Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology, 2016, 87, 2016-2025.	1.5	65
135	Cytokine expression and microglial activation in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2011, 17, 683-688.	1.1	64
136	Memory Impairment in Patients With Progressive Supranuclear Palsy. Archives of Neurology, 1989, 46, 765-767.	4.9	63
137	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nature Medicine, 2021, 27, 1451-1457.	15.2	63
138	Alzheimer's disease presenting as corticobasal syndrome. Movement Disorders, 2006, 21, 2018-2022.	2.2	62
139	Measuring quality of life in PSP: The PSP-QoL. Neurology, 2006, 67, 39-44.	1.5	61
140	Neuropsychological Features of Progressive Supranuclear Palsy. Brain and Cognition, 1995, 28, 311-320.	0.8	60
141	Diagnosis and Management of Progressive Supranuclear Palsy. Seminars in Neurology, 2001, 21, 041-048.	0.5	60
142	Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. Acta Neuropathologica, 2018, 136, 389-404.	3.9	59
143	Volumetric correlates of cognitive functioning in nondemented patients with Parkinson's disease. Movement Disorders, 2014, 29, 360-367.	2.2	55
144	Progressive supranuclear palsy: progression and survival. Journal of Neurology, 2016, 263, 380-389.	1.8	55

#	Article	IF	Citations
145	Progressive supranuclear palsy: Advances in diagnosis and management. Parkinsonism and Related Disorders, 2020, 73, 105-116.	1.1	55
146	Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Annals of Neurology, 1994, 36, 55-61.	2.8	54
147	Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy. Journal of Neural Transmission, 1998, 105, 217-227.	1.4	53
148	White-Matter Changes Correlate with Cognitive Functioning in Parkinsonâ€™s Disease. Frontiers in Neurology, 2013, 4, 37.	1.1	53
149	Environmental and occupational risk factors for progressive supranuclear palsy: Caseâ€control study. Movement Disorders, 2016, 31, 644-652.	2.2	53
150	Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment. Movement Disorders, 2018, 33, 503-510.	2.2	52
151	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.5	52
152	A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. Parkinsonism and Related Disorders, 2010, 16, 423-426.	1.1	50
153	Parkinson's Disease Mild Cognitive Impairment: Application and Validation of the Criteria. Journal of Parkinson's Disease, 2014, 4, 131-137.	1.5	50
154	Pupillary diameter assessment: Need for a graded scale. Neurology, 2000, 54, 530-530.	1.5	48
155	Parkinsonism and Frontotemporal Dementia: The Clinical Overlap. Journal of Molecular Neuroscience, 2011, 45, 343-349.	1.1	48
156	Impact of Mild Cognitive Impairment on Health-Related Quality of Life in Parkinson's Disease. Dementia and Geriatric Cognitive Disorders, 2013, 36, 67-75.	0.7	47
157	Corticobasal Degeneration. Seminars in Neurology, 2014, 34, 160-173.	0.5	47
158	Freezing of gait in postmortem-confirmed atypical parkinsonism. Movement Disorders, 2002, 17, 1041-1045.	2.2	46
159	Annonacin in Asimina triloba fruit: Implication for neurotoxicity. NeuroToxicology, 2012, 33, 53-58.	1.4	46
160	Physostigmine treatment of progressive supranuclear palsy. Annals of Neurology, 1989, 26, 404-407.	2.8	44
161	Preserved cognitive processes in cerebellar degeneration. Behavioural Brain Research, 1996, 79, 131-135.	1.2	44
162	Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. Annals of Clinical and Translational Neurology, 2020, 7, 449-461.	1.7	44

#	Article	IF	Citations
163	Abolishing the 1â€year rule: How much evidence will be enough?. Movement Disorders, 2016, 31, 1623-1627.	2.2	43
164	Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases. Alzheimer's and Dementia, 2020, 16, 118-130.	0.4	43
165	Neuropsychiatric assessment of Gilles de la Tourette patients: Comparative study with other hyperkinetic and hypokinetic movement disorders. Movement Disorders, 2001, 16, 1098-1104.	2.2	42
166	Serotonin Toxicity Association with Concomitant Antidepressants and Rasagiline Treatment: Retrospective Study (<scp>STACCATO</scp>). Pharmacotherapy, 2014, 34, 1250-1258.	1.2	42
167	Detecting Mild Cognitive Deficits in <scp>P</scp>arkinson's <scp>D</scp>isease: <scp>C</scp>omparison of <scp>N</scp>europsychological <scp>T</scp>ests. Movement Disorders, 2018, 33, 1750-1759.	2.2	42
168	Current directions in tau research: Highlights from Tau 2020. Alzheimer's and Dementia, 2022, 18, 988-1007.	0.4	42
169	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II. Journal of Neuropathology and Experimental Neurology, 2007, 66, 329-336.	0.9	41
170	Progression of Microstructural Degeneration in Progressive Supranuclear Palsy and Corticobasal Syndrome: A Longitudinal Diffusion Tensor Imaging Study. PLoS ONE, 2016, 11, e0157218.	1.1	40
171	Selective Deficits in Alzheimer and Parkinsonian Dementia: Visuospatial Function. Canadian Journal of Neurological Sciences, 1990, 17, 292-297.	0.3	39
172	Supranuclear gaze palsy and eyelid apraxia in postencephalitic parkinsonism. Journal of Neural Transmission, 1997, 104, 845-865.	1.4	39
173	Cognitive Impairment in Parkinsonâ€™s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors. Behavioral Sciences (Basel, Switzerland), 2021, 11, 74.	1.0	39
174	Update on progressive supranuclear palsy. Current Neurology and Neuroscience Reports, 2004, 4, 296-302.	2.0	38
175	Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: The GenePD Study. Neurology, 2006, 67, 2206-2210.	1.5	38
176	Neuropsychiatric Predictors of Cognitive Decline in Parkinson Disease: A Longitudinal Study. American Journal of Geriatric Psychiatry, 2017, 25, 279-289.	0.6	38
177	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 37-48.	0.4	38
178	Effects of Physostigmine on Spatial Attention in Patients With Progressive Supranuclear Palsy. Archives of Neurology, 1990, 47, 1346-1350.	4.9	37
179	Tau genotype: No effect on onset, symptom severity, or survival in progressive supranuclear palsy. Neurology, 2001, 57, 138-140.	1.5	37
180	The utility of the Mattis Dementia Rating Scale in Parkinson's disease mild cognitive impairment. Parkinsonism and Related Disorders, 2014, 20, 627-631.	1.1	37

#	Article	IF	Citations
181	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. Movement Disorders, 2020, 35, 171-176.	2.2	37
182	Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study. European Journal of Neurology, 1998, 5, 451-457.	1.7	36
183	Therapy and management of frontal lobe dementia patients. Neurology, 2001, 56, S41-5.	1.5	36
184	Roles of Education and IQ in Cognitive Reserve in Parkinsonâ€™s Disease-Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders Extra, 2012, 2, 343-352.	0.6	36
185	Tauopathy-Associated PERK Alleles are Functional Hypomorphs that Increase Neuronal Vulnerability to ER Stress. Human Molecular Genetics, 2018, 27, 3951-3963.	1.4	36
186	Nonâ€Invasive Sweatâ€Based Tracking of Lâ€Dopa Pharmacokinetic Profiles Following an Oral Tablet Administration. Angewandte Chemie - International Edition, 2021, 60, 19074-19078.	7.2	36
187	Recent advances in atypical parkinsonian disorders. Current Opinion in Neurology, 1999, 12, 441-446.	1.8	36
188	Effects of Physostigmine on Swallowing and Oral Motor Functions in Patients with Progressive Supranuclear Palsy: A Pilot Study. Dysphagia, 1999, 14, 165-168.	1.0	35
189	Replication of association between ELAVL4 and Parkinson disease: the GenePD study. Human Genetics, 2008, 124, 95-99.	1.8	34
190	Biology and Neuropathology of Dementia in Syphilis and Lyme Disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 825-844.	1.0	34
191	Long-duration Parkinson's disease: Role of lateralization of motor features. Parkinsonism and Related Disorders, 2013, 19, 77-80.	1.1	34
192	Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status. Parkinsonism and Related Disorders, 2014, 20, 503-507.	1.1	34
193	Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine. Neurology, 2018, 91, 797-799.	1.5	34
194	Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome. Alzheimer's and Dementia, 2019, 15, 1218-1228.	0.4	34
195	Progressive supranuclear palsy. Neurology, 1991, 41, 1257-1257.	1.5	34
196	Cognition among individuals along a spectrum of increased risk for Parkinsonâ€™s disease. PLoS ONE, 2018, 13, e0201964.	1.1	33
197	Cognitive and neuropsychiatric effects of subthalamotomy for Parkinsonâ€™s disease. Parkinsonism and Related Disorders, 2010, 16, 535-539.	1.1	32
198	Risk of Parkinson's disease dementia related to level I MDS PDâ€MCI. Movement Disorders, 2019, 34, 430-435.	2.2	32

#	Article	IF	Citations
199	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€EXAMINER as a potential clinical trial endpoint. Alzheimer's and Dementia, 2020, 16, 11-21.	0.4	32
200	Wearable electrochemical microneedle sensing platform for real-time continuous interstitial fluid monitoring of apomorphine: Toward Parkinson management. Sensors and Actuators B: Chemical, 2022, 354, 131234.	4.0	32
201	Caregiving in progressive supranuclear palsy. Neurology, 1998, 51, 1303-1309.	1.5	31
202	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <scp>Movement Disorder Society</scp> Multiple System Atrophy Study Group. Movement Disorders Clinical Practice, 2020, 7, 750-762.	0.8	31
203	The Progressive Supranuclear Palsy Clinical Deficits Scale. Movement Disorders, 2020, 35, 650-661.	2.2	31
204	Clinical and Genetic Aspects of Progressive Supranuclear Palsy. Journal of Geriatric Psychiatry and Neurology, 1998, 11, 107-114.	1.2	30
205	Scientific position paper of the Movement Disorder Society evaluation of surgery for Parkinson's disease. Movement Disorders, 2000, 15, 436-438.	2.2	30
206	Rate of decline in progressive supranuclear palsy. Movement Disorders, 2014, 29, 463-468.	2.2	30
207	Proposed research criteria for prodromal behavioural variant frontotemporal dementia. Brain, 2022, 145, 1079-1097.	3.7	30
208	Research goals in progressive supranuclear palsy. Movement Disorders, 2000, 15, 446-458.	2.2	29
209	A disposable electrochemical biosensor for l-DOPA determination in undiluted human serum. Electrochemistry Communications, 2014, 48, 28-31.	2.3	29
210	Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care. Frontiers in Neurology, 2021, 12, 694872.	1.1	29
211	Predictors of performance-based measures of instrumental activities of daily living in nondemented patients with Parkinsonâ€™s disease. Journal of Clinical and Experimental Neuropsychology, 2013, 35, 926-933.	0.8	28
212	Clinical symptoms in Alzheimer's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 207-216.	1.0	27
213	Aberrant Intrinsic Activity and Connectivity in Cognitively Normal Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2017, 9, 197.	1.7	27
214	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 49-59.	0.4	27
215	Can tropicamide eye drop response differentiate patients with progressive supranuclear palsy and Alzheimer's disease from healthy control subjects?. Neurology, 1996, 47, 1324-1326.	1.5	26
216	Unique white matter structural connectivity in early-stage drug-naive Parkinson disease. Neurology, 2020, 94, e774-e784.	1.5	24

#	Article	IF	Citations
217	Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease. Parkinsonism and Related Disorders, 2016, 27, 54-60.	1.1	23
218	Sex differences for phenotype in pathologically defined dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 745-750.	0.9	23
219	A Microstirring Pill Enhances Bioavailability of Orally Administered Drugs. Advanced Science, 2021, 8, 2100389.	5.6	23
220	Revised Self-Monitoring Scale. Neurology, 2020, 94, e2384-e2395.	1.5	23
221	Yes/no reversals as neurobehavioral sequela: a disorder of language, praxis, or inhibitory control?. European Journal of Neurology, 2003, 10, 103-106.	1.7	22
222	Unraveling progressive supranuclear palsy: from the bedsideback to the bench. Parkinsonism and Related Disorders, 2007, 13, S341-S346.	1.1	22
223	Traumatic Brain Injury and Firearm Use and Risk of Progressive Supranuclear Palsy Among Veterans. Frontiers in Neurology, 2018, 9, 474.	1.1	22
224	The virtual reality of Parkinson's disease freezing of gait: A systematic review. Parkinsonism and Related Disorders, 2019, 61, 26-33.	1.1	22
225	Behcet's syndrome masquerading as tumor. Neuroradiology, 1987, 29, 103-103.	1.1	21
226	Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability. Parkinsonism and Related Disorders, 2019, 66, 87-93.	1.1	21
227	Brain volumetric deficits in MAPT mutation carriers: a multisite study. Annals of Clinical and Translational Neurology, 2021, 8, 95-110.	1.7	21
228	Worldwide barriers to genetic testing for movement disorders. European Journal of Neurology, 2021, 28, 1901-1909.	1.7	21
229	Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials. Frontiers in Neurology, 2021, 12, 648532.	1.1	21
230	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Reports Medicine, 2022, 3, 100607.	3.3	21
231	The clinical and pathologic hallmarks of progressive supranuclear palsy. Current Opinion in Neurology, 1997, 10, 346-350.	1.8	20
232	Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report. Movement Disorders Clinical Practice, 2015, 2, 127-134.	0.8	20
233	Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers). Quality of Life Research, 2016, 25, 81-88.	1.5	20
234	Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy. Expert Opinion on Investigational Drugs, 2018, 27, 349-361.	1.9	20

#	Article	IF	Citations
235	Transcriptional analysis of peripheral memory T cells reveals Parkinsonâ€™s disease-specific gene signatures. Npj Parkinson's Disease, 2022, 8, 30.	2.5	20
236	Does reversed laterality really exist in dextrals? A case study. Neuropsychologia, 1986, 24, 241-254.	0.7	19
237	Parkinsonian Features. JAMA - Journal of the American Medical Association, 1998, 280, 1654.	3.8	19
238	Current and future treatments in progressive supranuclear palsy. Current Treatment Options in Neurology, 2006, 8, 211-223.	0.7	19
239	Dissociation of Neural Mechanisms for Intersensory Timing Deficits in Parkinsonâ€™s Disease. Timing and Time Perception, 2014, 2, 145-168.	0.4	19
240	Frontrunner in Translation: Progressive Supranuclear Palsy. Frontiers in Neurology, 2019, 10, 1125.	1.1	19
241	Closing the loop for patients with Parkinson disease: where are we?. Nature Reviews Neurology, 2022, 18, 497-507.	4.9	19
242	Cognitive and behavioral aspects of PSP since Steele, Richardson and Olszewskiâ€™s description of PSP 40 years ago and Albertâ€™s delineation of the subcortical dementia 30 years ago. Neurocase, 2005, 11, 250-262.	0.2	18
243	The Epidemiology of vascular dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 639-658.	1.0	18
244	Estimating the Evolution of Disease in the Parkinsonâ€™s Progression Markers Initiative. Neurodegenerative Diseases, 2018, 18, 173-190.	0.8	18
245	Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?. Parkinsonism and Related Disorders, 2019, 69, 34-39.	1.1	18
246	Orthostatic Hypotension Is Associated With Cognitive Decline in Parkinson Disease. Frontiers in Neurology, 2020, 11, 897.	1.1	18
247	Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine.. Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 832-835.	0.9	15
248	Rapidly progressive atypical parkinsonism associated with frontotemporal lobar degeneration and motor neuron disease. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 751-753.	0.9	15
249	The pill questionnaire in a nondemented Parkinson's disease population. Movement Disorders, 2012, 27, 1308-1311.	2.2	15
250	Cognition in movement disorders: Where can we hope to be in ten years?. Movement Disorders, 2014, 29, 704-711.	2.2	15
251	Structural MRI Correlates of Episodic Memory Processes in Parkinsonâ€™s Disease Without Mild Cognitive Impairment. Journal of Parkinson's Disease, 2015, 5, 971-981.	1.5	15
252	Understanding falls in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2017, 35, 75-81.	1.1	15

#	Article	IF	Citations
253	Does the Geriatric Depression Scale measure depression in Parkinson's disease?. International Journal of Geriatric Psychiatry, 2018, 33, 1662-1670.	1.3	15
254	Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinsonâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2019, 47, 187-197.	0.7	15
255	Neuropsychiatric symptoms and their impact on quality of life in multiple system atrophy. Cogent Psychology, 2016, 3, 1131476.	0.6	14
256	Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. Movement Disorders, 2018, 33, 468-472.	2.2	14
257	Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment. Movement Disorders, 2018, 33, 520-527.	2.2	14
258	Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy. Movement Disorders, 2019, 34, 1655-1662.	2.2	14
259	Abnormal distraction and loadâ€specific connectivity during working memory in cognitively normal Parkinson's disease. Human Brain Mapping, 2020, 41, 1195-1211.	1.9	14
260	Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database. Frontiers in Neurology, 2021, 12, 571800.	1.1	14
261	Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders. Neurology, 2021, 97, e814-e824.	1.5	14
262	Functional impairment in progressive supranuclear palsy. Neurology, 2013, 80, 380-384.	1.5	13
263	Psychometric Properties and Characteristics of the Northâ€East Visual Hallucinations Interview in Parkinson's Disease. Movement Disorders Clinical Practice, 2017, 4, 717-723.	0.8	13
264	Factor Analysis of the Apathy Scale in Parkinson's Disease. Movement Disorders Clinical Practice, 2019, 6, 379-386.	0.8	13
265	A lack of the R406W tau mutation in progressive supranuclear palsy and corticobasal degeneration. Neurology, 1999, 52, 404-404.	1.5	13
266	Dysfunction of Ib (Autogenic) spinal inhibition in patients with progressive supranuclear palsy. Movement Disorders, 1998, 13, 668-672.	2.2	12
267	Impairment of eyeblink classical conditioning in progressive supranuclear palsy. Movement Disorders, 2001, 16, 240-251.	2.2	12
268	Neuropathology of Pick body disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 415-430.	1.0	12
269	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 671-686.	1.0	12
270	Brain-Lung-Thyroid Disease. Journal of Child Neurology, 2012, 27, 68-73.	0.7	12

#	Article	IF	Citations
271	Hypertension and progressive supranuclear palsy. Parkinsonism and Related Disorders, 2019, 66, 166-170.	1.1	12
272	Nonlinear Zâ€score modeling for improved detection of cognitive abnormality. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 797-808.	1.2	12
273	Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia. Cortex, 2021, 139, 99-115.	1.1	12
274	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology, 2021, 12, 805135.	1.1	12
275	Sex Differences for Clinical Correlates of Alzheimer's Pathology in People with Lewy Body Pathology. Movement Disorders, 2022, 37, 1505-1515.	2.2	12
276	What can artificial neural networks teach us about neurodegenerative disorders with extrapyramidal features?. Brain, 1996, 119, 831-839.	3.7	11
277	Ideomotor apraxia in progressive supranuclear palsy: A case study. Movement Disorders, 1999, 14, 162-166.	2.2	11
278	Clinical aspects and biology of normal pressure hydrocephalus. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 887-902.	1.0	11
279	Relationship between uric acid levels and progressive supranuclear palsy. Movement Disorders, 2016, 31, 663-667.	2.2	11
280	Clinical-Neuropathological Correlations of Alzheimerâ€™s Disease and Related Dementias in Latino Volunteers. Journal of Alzheimer's Disease, 2018, 66, 1539-1548.	1.2	11
281	The role of dispositional mindfulness in a stress-health pathway among Parkinsonâ€™s disease patients and caregiving partners. Quality of Life Research, 2019, 28, 2705-2716.	1.5	11
282	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. Parkinsonism and Related Disorders, 2020, 79, 121-126.	1.1	11
283	Hispanic Perspectives on Parkinsonâ€™s Disease Care and Research Participation. Journal of Alzheimer's Disease, 2021, 81, 809-819.	1.2	11
284	Level I <scp>PDâ€MCI</scp> Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia. Movement Disorders Clinical Practice, 2022, 9, 479-483.	0.8	11
285	Neuropathology of Hereditary Forms of Frontotemporal Dementia and Parkinsonism. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 393-414.	1.0	10
286	Pan-American Consortium of Multiple System Atrophy (PANMSA). A Pan-American multicentre cohort study of Multiple System Atrophy. Journal of Parkinson's Disease, 2014, 4, 693-698.	1.5	10
287	Altered Functional Interactions of Inhibition Regions in Cognitively Normal Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 331.	1.7	10
288	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. Parkinsonism and Related Disorders, 2020, 80, 127-132.	1.1	10

#	Article	IF	Citations
289	Progressive Supranuclear Palsy and Corticobasal Degeneration. Advances in Experimental Medicine and Biology, 2021, 1281, 151-176.	0.8	10
290	Patterns and predictors of referrals to allied health services for individuals with Parkinson's disease: A Parkinson's foundation (PF) QII study. Parkinsonism and Related Disorders, 2021, 83, 115-122.	1.1	10
291	The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. Npj Parkinson's Disease, 2021, 7, 16.	2.5	10
292	Nonâ€Invasive Sweatâ€Based Tracking of Lâ€Dopa Pharmacokinetic Profiles Following an Oral Tablet Administration. Angewandte Chemie, 2021, 133, 19222-19226.	1.6	10
293	Apolipoprotein Eepsilon4 (Epsilon) Allele Does Not Affect the Onset or Symptom Severity in Progressive Supranuclear Palsy. Archives of Neurology, 1998, 55, 752-754.	4.9	10
294	Examining the motor phenotype of patients with both essential tremor and Parkinson's disease. Tremor and Other Hyperkinetic Movements, 2012, 2, .	1.1	10
295	An open letter to the Committee on The Nobel Prize in Medicine. Parkinsonism and Related Disorders, 2001, 7, 149-155.	1.1	9
296	Swallowing disturbances in the corticobasal syndrome. Parkinsonism and Related Disorders, 2015, 21, 1342-1348.	1.1	9
297	[O2â€“17â€“01]: RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBOâ€CONTROLLED STUDY OF ABBVâ€8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P599.	0.4	9
298	Neuroimaging and neuropsychological assessment of freezing of gait in Parkinson's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 387-394.	1.8	9
299	Occupation and Parkinson disease in the Women's Health Initiative Observational Study. American Journal of Industrial Medicine, 2019, 62, 766-776.	1.0	9
300	Lewy Body Dementia Associationâ€™s Research Centers of Excellence Program: Inaugural Meeting Proceedings. Alzheimer's Research and Therapy, 2019, 11, 23.	3.0	9
301	Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. Parkinsonism and Related Disorders, 2020, 78, 56-60.	1.1	9
302	Parkinson disease with mild cognitive impairment: Domainâ€specific cognitive complaints predict dementia. Acta Neurologica Scandinavica, 2020, 142, 585-596.	1.0	9
303	Clinical and pathologic features of cognitive-predominant corticobasal degeneration. Neurology, 2020, 95, e35-e45.	1.5	9
304	The contribution of behavioral features to caregiver burden in FTLD spectrum disorders. Alzheimer's and Dementia, 2022, 18, 1635-1649.	0.4	9
305	A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. Movement Disorders, 2022, 37, 1265-1271.	2.2	9
306	Differential impact of individual autonomic domains on clinical outcomes in Parkinsonâ€™s disease. Journal of Neurology, 2022, 269, 5510-5520.	1.8	9

#	Article	IF	Citations
307	Clinical Spectrum of Tauopathies. Frontiers in Neurology, 0, 13, .	1.1	9
308	What can preservation of autobiographic memory after muscarinic blockade tell us about the scopolamine model of dementia?. Neurology, 1995, 45, 387-389.	1.5	8
309	Update of atypical parkinsonian disorders. Current Opinion in Neurology, 2007, 20, 434-437.	1.8	8
310	Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: The GenePD study. Movement Disorders, 2008, 23, 1596-1601.	2.2	8
311	Correcting for Demographic Variables on the Modified Telephone Interview for Cognitive Status. American Journal of Geriatric Psychiatry, 2014, 22, 1438-1443.	0.6	8
312	End of life planning in parkinsonian diseases. Parkinsonism and Related Disorders, 2019, 62, 73-78.	1.1	8
313	Environmental Risk Factors for Progressive Supranuclear Palsy. Journal of Movement Disorders, 2021, 14, 103-113.	0.7	8
314	Methodological and Research Issues in the Evaluation of Biological Diagnostic Markers for Alzheimerâ€™s Disease. Neurobiology of Aging, 1998, 19, 121-123.	1.5	7
315	Primary Health Care Providers' Knowledge Gaps on Parkinson's Disease. Educational Gerontology, 2013, 39, 856-862.	0.7	7
316	Cognitive functioning in individuals with Parkinsonâ€™s disease and traumatic brain injury: A longitudinal study. Parkinsonism and Related Disorders, 2016, 30, 58-61.	1.1	7
317	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism and Related Disorders, 2019, 60, 138-145.	1.1	7
318	Lowering the risk of Parkinsonâ€™s disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes. Brain, 2020, 143, 2868-2871.	3.7	7
319	Career Development Program for Underrepresented in Medicine Scholars in Academic Neurology. Neurology, 2021, 97, 125-133.	1.5	7
320	What is an Atypical Parkinsonian Disorder?. , 2005, , 1-9.		6
321	The Neuropathology of Vascular and Mixed Dementia and Vascular Cognitive Impairment. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 687-703.	1.0	6
322	Current and future therapeutic approaches in progressive supranuclear palsy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 493-508.	1.0	6
323	History of Dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 3-13.	1.0	6
324	H1/H1 genotype influences symptom severity in corticobasal syndrome. Movement Disorders, 2010, 25, 760-763.	2.2	6

#	Article	IF	Citations
325	Pathophysiology, genetics, clinical features, diagnosis and therapeutic trials in progressive supranuclear palsy. Expert Opinion on Orphan Drugs, 2015, 3, 253-265.	0.5	6
326	Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis. Movement Disorders Clinical Practice, 2016, 3, 65-67.	0.8	6
327	Genetic influences on cognition in progressive supranuclear palsy. Movement Disorders, 2017, 32, 1764-1771.	2.2	6
328	Anti-inflammatory drug use and progressive supranuclear palsy. Parkinsonism and Related Disorders, 2018, 48, 89-92.	1.1	6
329	Progress in the treatment of Parkinson-Plus syndromes. Parkinsonism and Related Disorders, 2019, 59, 101-110.	1.1	6
330	Pathologyâ€Proven Corticobasal Degeneration Presenting as Richardson's Syndrome. Movement Disorders Clinical Practice, 2020, 7, 267-272.	0.8	6
331	Delineation of Apathy Subgroups in Parkinson's Disease: Differences in Clinical Presentation, Functional Ability, Healthâ€related Quality of Life, and Caregiver Burden. Movement Disorders Clinical Practice, 2021, 8, 92-99.	0.8	6
332	CSF galanin and neuropeptide Y immunoreactivity in progressive supranuclear palsy. Acta Neurologica Scandinavica, 1992, 86, 204-206.	1.0	5
333	Is EEG useful in the differential diagnosis of parkinsonism?. Parkinsonism and Related Disorders, 1998, 4, 79-80.	1.1	5
334	Clinical and Therapeutic Aspects of Dementia in Syphilis and Lyme Disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 819-823.	1.0	5
335	Therapeutic options for Progressive Supranuclear Palsy including investigational drugs. Expert Opinion on Orphan Drugs, 2017, 5, 575-587.	0.5	5
336	The Wearable Multimodal Monitoring System: A Platform to Study Falls and Near-Falls in the Real-World. Lecture Notes in Computer Science, 2015, , 412-422.	1.0	5
337	Differences in Motor Features of C9orf72 , MAPT , or GRN Variant Carriers With Familial Frontotemporal Lobar Degeneration. Neurology, 2022, 99, .	1.5	5
338	ATYPICAL PARKINSONIAN DISORDERS. CONTINUUM Lifelong Learning in Neurology, 2004, 10, 42-64.	0.4	4
339	Quality of Life in Dementias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 97-100.	1.0	4
340	The Role of Stress as a Risk Factor for Progressive Supranuclear Palsy. Journal of Parkinson's Disease, 2017, 7, 377-383.	1.5	4
341	Prominent Tongue and Jaw Tremor in a Patient with Probable Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2018, 5, 99-100.	0.8	4
342	Medication Management Performance in Parkinsonâ€™s Disease: Examination of Process Errors. Archives of Clinical Neuropsychology, 2021, 36, 1307-1315.	0.3	4

#	Article	IF	Citations
343	Semantic Recollection in Parkinsonâ€™s Disease: Functional Reconfiguration and MAPT Variants. Frontiers in Aging Neuroscience, 2021, 13, 727057.	1.7	4
344	Internetwork Connectivity Predicts Cognitive Decline in Parkinsonâ€™s and Is Altered by Genetic Variants. Frontiers in Aging Neuroscience, 2022, 14, 853029.	1.7	4
345	Toward magnetic resonance imaging biomarkers for progressive supranuclear palsy and multisystem atrophy. Movement Disorders, 2012, 27, 1711-1713.	2.2	3
346	Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study. BMC Medical Genetics, 2012, 13, 16.	2.1	3
347	Neuropsychiatric and cognitive disorders in other parkinsonian disorders. , 2013, , 261-274.		3
348	LevodopaâEResponsive Parkinsonism Associated with Giant VirchowâERobin Spaces: A Case Report. Movement Disorders Clinical Practice, 2017, 4, 619-622.	0.8	3
349	Dopamine effects on memory load and distraction during visuospatial working memory in cognitively normal Parkinsonâ€™s disease. Aging, Neuropsychology, and Cognition, 2021, 28, 812-828.	0.7	3
350	Orthostatic hypotension preceding dementia with Lewy bodies by over 15Âyears: a clinicopathologic case report. Clinical Autonomic Research, 2020, 30, 575-577.	1.4	3
351	Two Patients with Niemann Pick Disease Type C Diagnosed in the Seventh Decade of Life. Movement Disorders Clinical Practice, 2020, 7, 961-964.	0.8	3
352	Informant-Reported Cognitive Decline is Associated with Objective Cognitive Performance in Parkinsonâ€™s Disease. Journal of the International Neuropsychological Society, 2021, 27, 439-449.	1.2	3
353	Diagnostic issues in non-AD dementias. Clinical Neuroscience Research, 2004, 3, 363-374.	0.8	2
354	Perspectives of Alzheimer's disease treatments. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 273-290.	1.0	2
355	Neuropathology and genetics of corticobasal degeneration. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 523-532.	1.0	2
356	Reply: Mild cognitive impairment in de novo Parkinson's disease according to Movement Disorder guidelines. Movement Disorders, 2012, 27, 1707-1707.	2.2	2
357	Changes in Self- and Informant-Reported Frontal Behaviors in Parkinsonâ€™s Disease: A Longitudinal Study. Journal of Geriatric Psychiatry and Neurology, 2022, 35, 89-101.	1.2	2
358	Progressive Supranuclear Palsy and Statin Use. Movement Disorders, 2020, 35, 1253-1257.	2.2	2
359	Assessment of Motor Dysfunction with Virtual Reality in Patients Undergoing [123I]FP-CIT SPECT/CT Brain Imaging. Tomography, 2021, 7, 95-106.	0.8	2
360	Association of Stress-Health Factors among Parkinsonâ€™s Disease Patient/Caregiving-Partner Dyads. Archives of Clinical Neuropsychology, 2022, 37, 12-18.	0.3	2

#	Article	IF	Citations
361	Cerebellar cognition. Neurology, 1993, 43, 2153.	1.5	2
362	<scp>Physicianâ€Assisted</scp> Dying: Access and Utilization in Patients with Movement Disorders. Movement Disorders, 2022, 37, 694-698.	2.2	2
363	Unilateral left cerebral deterioration documented by CT, MRI, and neuropsychological studies: A possible case of pick's disease. Developmental Neuropsychology, 1988, 4, 295-302.	1.0	1
364	Atypical parkinsonism in the French West Indies. Lancet, The, 1999, 354, 1472-1473.	6.3	1
365	Neurobiology of Progressive Supranuclear Palsy. , 2007, , 105-110.		1
366	Clinical aspects of Parkinson dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 303-306.	1.0	1
367	Measuring quality of life in progressive supranuclear palsy. , 2011, , 52-59.		1
368	The meaning of a â€œhippoâ€•response on the Montreal Cognitive Assessment in Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 463-465.	1.1	1
369	At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease. Movement Disorders, 2018, 33, 501-502.	2.2	1
370	B-18 Executive Functioning Best Predicts Performance-Based Financial Skills in Non-Demented Parkinsonâ€™s Disease. Archives of Clinical Neuropsychology, 2019, 34, 963-963.	0.3	1
371	Treatment of Progressive Supranuclear Palsy. Current Clinical Neurology, 2019, , 137-140.	0.1	1
372	Gene-Environment Interactions in Progressive Supranuclear Palsy. Frontiers in Neurology, 2021, 12, 664796.	1.1	1
373	Progressive Supranuclear Palsy and Corticobasal Degeneration. , 2005, , 505-514.		1
374	Investigational therapeutics for the treatment of progressive supranuclear palsy. Expert Opinion on Investigational Drugs, 2022, 31, 813-823.	1.9	1
375	641 Accuracy of the clinical diagnosis of pick's disease. Neurobiology of Aging, 1996, 17, S159-S160.	1.5	0
376	Limb shaking in multiple system atrophy. European Journal of Neurology, 1998, 5, 113-115.	1.7	0
377	Clinicopathologic Case Report. Journal of Neuropsychiatry and Clinical Neurosciences, 1999, 11, 107-112.	0.9	0
378	Preface. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, ix.	1.0	0

#	Article	IF	Citations
379	Progressive supranuclear palsy and corticobasal degeneration: similarities and differences. Future Neurology, 2008, 3, 299-307.	0.9	0
380	Reply: Corticobasal syndrome with Alzheimer's disease pathology. Movement Disorders, 2009, 24, 153-153.	2.2	0
381	Woman with gait impairment and difficulty reading. , 0, , 229-237.		0
382	Head injury exposure in PSP: a case-control study. Journal of the Neurological Sciences, 2015, 357, e275.	0.3	0
383	P1â€433: GRAY MATTER DEFICITS IN SYMPTOMATIC AND PRESYMPTOMATIC MAPT MUTATION CARRIERS. Alzheimer's and Dementia, 2018, 14, P475.	0.4	0
384	The complexity of DLB: U.S.â€based Dementia with Lewy Body Consortium. Alzheimer's and Dementia, 2020, 16, e042846.	0.4	0
385	Studying the natural history of frontotemporal lobar degeneration (FTLD): The ARTFL LEFFTDS longitudinal FTLD (ALLFTD) protocol. Alzheimer's and Dementia, 2020, 16, e045482.	0.4	0
386	Plasma neurofilament light chain levels reflect caregiver burden and social cognition measures in familial frontotemporal lobar degeneration (FTLD). Alzheimer's and Dementia, 2020, 16, e046247.	0.4	0
387	Reply to: â€œLaryngeal Movement Disorders in Multiple System Atrophy: A Diagnostic Biomarker?â€. Movement Disorders, 2021, 36, 1999-2000.	2.2	0
388	Verifying Clinical Criteria for Parkinsonian Disorders with CART Decision Trees. Lecture Notes in Computer Science, 2004, , 1018-1024.	1.0	0
389	Is it PD, PSP, CBD, DLB, or MSA?. , 2008, , 219-222.		0
390	Parkinsonâ€™s Disease: An Overview of Pathogenesis. , 2009, , 159-178.		0
391	Resting state functional connectivity in levodopa non responsive Parkinson's disease patients with freezing of gait. Parkinsonism and Related Disorders, 2020, 79, e8.	1.1	0
392	Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia. Neurology, 2022, , 10.1212/WNL.0000000000200582.	1.5	0
393	A Pilot Randomized Controlled Trial Investigating MBSR for Parkinsonâ€™s Disease Patients and Their Caregiving Partners: Effects on Distress, Social support, Cortisol, and Inflammation. Mindfulness, 2022, 13, 1271-1280.	1.6	0